CorMedix Inc. (CRMD)
CRMD Stock Price Chart
Explore CorMedix Inc. interactive price chart. Choose custom timeframes to analyze CRMD price movements and trends.
CRMD Company Profile
Discover essential business fundamentals and corporate details for CorMedix Inc. (CRMD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 May 2010
Employees
64.00
Website
https://www.cormedix.comCEO
Joseph Todisco
Description
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
CRMD Financial Timeline
Browse a chronological timeline of CorMedix Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $0.26, while revenue estimate is $96.04m.
Earnings released on 14 May 2026
EPS came in at $0.43 surpassing the estimated $0.35 by +22.86%, while revenue for the quarter reached $127.40m , beating expectations by +21.38%.
Earnings released on 5 Mar 2026
EPS came in at $0.61 falling short of the estimated $0.86 by -29.07%, while revenue for the quarter reached $128.62m , beating expectations by +1.26%.
Earnings released on 12 Nov 2025
EPS came in at $0.57 surpassing the estimated $0.48 by +18.75%, while revenue for the quarter reached $104.28m , missing expectations by -17.91%.
Earnings released on 7 Aug 2025
EPS came in at $0.28 surpassing the estimated $0.20 by +40.00%, while revenue for the quarter reached $39.74m , missing expectations by -6.41%.
Earnings released on 6 May 2025
EPS came in at $0.30 surpassing the estimated $0.25 by +20.00%, while revenue for the quarter reached $39.08m , beating expectations by +30.80%.
Earnings released on 25 Mar 2025
EPS came in at $0.22 surpassing the estimated $0.17 by +29.41%, while revenue for the quarter reached $31.21m , missing expectations by -0.19%.
Earnings released on 30 Oct 2024
EPS came in at -$0.05 surpassing the estimated -$0.10 by +50.00%, while revenue for the quarter reached $11.46m , missing expectations by -42.11%.
Earnings released on 14 Aug 2024
EPS came in at -$0.25 surpassing the estimated -$0.26 by +3.85%, while revenue for the quarter reached $806.12k , missing expectations by -51.73%.
Earnings released on 9 May 2024
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%.
Earnings released on 12 Mar 2024
EPS came in at -$0.26 falling short of the estimated -$0.21 by -23.81%, while revenue for the quarter reached $304.11k , beating expectations by +221.64%.
Earnings released on 14 Nov 2023
EPS came in at -$0.17 surpassing the estimated -$0.21 by +19.05%.
Earnings released on 8 Aug 2023
EPS came in at -$0.25 falling short of the estimated -$0.22 by -13.64%.
Earnings released on 15 May 2023
EPS came in at -$0.24 falling short of the estimated -$0.20 by -20.00%.
Earnings released on 30 Mar 2023
EPS came in at -$0.20 falling short of the estimated -$0.19 by -5.26%, while revenue for the quarter reached $29.70k , beating expectations by +1.17k%.
Earnings released on 10 Nov 2022
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%, while revenue for the quarter reached $6.82k .
Earnings released on 11 Aug 2022
EPS came in at -$0.19 surpassing the estimated -$0.20 by +5.00%, while revenue for the quarter reached $21.25k .
Earnings released on 12 May 2022
EPS came in at -$0.18 surpassing the estimated -$0.23 by +21.74%, while revenue for the quarter reached $7.64k , missing expectations by -69.46%.
Earnings released on 29 Mar 2022
EPS came in at -$0.20 surpassing the estimated -$0.22 by +9.09%, while revenue for the quarter reached $56.40k , beating expectations by +196.83%.
Earnings released on 9 Nov 2021
EPS came in at -$0.22 falling short of the estimated -$0.18 by -22.22%, while revenue for the quarter reached $38.09k , beating expectations by +90.44%.
Earnings released on 12 Aug 2021
EPS came in at -$0.12 surpassing the estimated -$0.18 by +33.33%, while revenue for the quarter reached $8.19k , missing expectations by -79.52%.
CRMD Stock Performance
Access detailed CRMD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
